Therapeutic Response

FIP1L1::PDGFRA status confers therapeutic sensitivity to Imatinib in patients with Gastrointestinal Stromal Tumor.

Statements

Source and description
Gleevec (imatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to imatinib for the adjuvant treatment of adult patients following resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST).